RUTGERS
Rutgers Environmental Health and Safety

Rutgers Environmental Health & Safety
Rutgers, The State University of New Jersey
185 South Orange Avenue – MSB Room A534
Newark, New Jersey 07101

http://rehs.rutgers.edu
Phone: 973-972-5305
Fax: 973-972-6498

ANNUAL REPORT / RENEWAL - INVESTIGATIONAL HUMAN–USE APPLICATION APPROVED TO USE RADIOACTIVE MATERIALS (RAM) AND/OR RADIOGRAPHIC MACHINES

(**Check boxes wherever applicable**)

RAM only ☐ **RADIOGRAPHIC MACHINES only** ☐ **RAM & MACHINES** ☐

1) TITLE OF THE RESEARCH PROJECT:

2) PRINCIPAL INVESTIGATOR (PI) Information (Please Print Clearly) :

Last Name: First Name: M.I.

Title: Department:

Office Location: E-mail:

Office Phone # Emergency Phone # Lab Phone #

3) Number of Human Research Subjects Studied **since last renewal** (12/1/20 to 11/30/20) :

4) Cumulative Number of Human Research Subjects Studied over the Lifetime of this Protocol :

5) Since the last review, have **any unanticipated problems involving risks to subjects or others and/or serious adverse events occurred** that have not been previously reported?

Yes ☐ No ☐ *If yes, please attach a copy of detailed explanation of each event.*

6) Since the last review, were **the radiation doses within the specifications of the approved protocol for all subjects**?

Yes ☐ No ☐ *If No, please provide detailed calculation of absorbed doses and effective doses for each research subject that exceeded the dose estimates in the approved protocol. Dosimetry for radiopharmaceuticals should include absorbed dose and equivalent dose to whole body, active blood-forming organs, lens of the eye, gonads, and other organ doses. Also provide effective dose.*

7) Was a claim of confidentiality made?

Yes ☐ No ☐ **Note:** *Contents of these reports will be made available for public disclosure unless confidentiality is requested by the investigator and it is adequately shown by the investigator that the report constitutes a trade secret or confidential commercial information.*

8) Signature below affirms that the Principal Investigator will comply with the requirements set forth by the Radiation Safety Committee for the use of radionuclides and machine sources of ionizing radiation. Furthermore, the Principal Investigator shall notify the Human Use Subcommittee of the Radiation Safety Committee immediately of any adverse reactions that may be attributable to radiopharmaceuticals or machine source radiation administered to their research subjects.

In case of prolonged absence or termination, the Principal Investigator must notify the REHS-Radiation Safety Officer by telephone 973-972-5305 or E-Mail: Prasad.Neti@rutgers.edu.

Signature Date